Physiology and Pharmacology

Lee E. Faber, Ph.D.

EDUCATION AND TRAINING:
B.S. -Education and Training
1964 A.B.Zoology, Duke University, Durham, NC, USA
1967 M.S., Biology, Bowling Green State University, Bowling Green, OH, USA
1970 Ph.D., Zoology, Indiana University, Bloomington, IN, USA

EMPLOYMENT:

1994 - present Medical University of Ohio, Toledo, Ohio Department of Physiology & Molecular Medicine, Professor, Full-Time
1990 - present Medical University of Ohio, Toledo, Ohio, Department of Obstetrics and Gynecology, Professor, Full-Time
1978 - 1989 Medical University of Ohio, Toledo, Ohio, Department of Obstetrics and Gynecology, Department of Physiology, Associate Professor - With Tenure, Full-Time
1974 - 1994 Medical University of Ohio, Toledo, Ohio, Director, Endocrine Research, Department of Obstetrics and Gynecology, Full-time
1975 - 1978 Medical University of Ohio, Toledo, Ohio, Department of Obstetrics and Gynecology, Department of Physiology, Assistant Professor, Full-time
1974 - 1975 Medical University of Ohio, Toledo, Ohio, Department of Obstetrics and Gynecology, Department of Physiology, Research Assistant Professor, Full-time
1973 - 1974 Institute of Medical Research of The Toledo Hospital, Toledo, Ohio, Acting Director, Full-time
1971 - 1974 Medical University of Ohio, Toledo, Ohio, Department of Physiology, Adjunct Instructor to Adjunct, Assistant Professor, Volunteer
1971 - 1974 Institute of Medical Research of The Toledo Hospital, Toledo, Ohio, Senior Research Fellow, Full-time
1966 - 1968 Indiana University, Bloomington, Indiana, Teaching Assistant, Part-time
1965 - 1966 Bowling Green State University, Bowling Green, Ohio, Research Assistant, Part-time

PRE- AND POSTDOCTORAL FELLOWSHIPS:
1968 - 1969 Indiana University; Zoology, National Science Foundation (From 1968 to 1969)
1969 - 1971 Syntex Research; Steroid Biochemistry, Syntex Research (From 1969 to 1971)
2000 MUO Teaching Scholars Fellowship Program 2000

NATIONAL AND INTERNATIONAL PROFESSIONAL SOCIETIES AND ACTIVITIES:
1964 American Association for the Advancement of Science (AAAS)
1967 American Society of Zoologists
1972 Ohio Academy of Science
1975 Endocrine Society
1976 Sigma Xi
1976 Society for the Study of Reproduction

EDITORIAL BOARDS, JOURNAL, REVIEWER, ECT.:
1. Archives Biochemistry and Biophysics
2. Endocrinology
3. Science
4. Biochemistry
5. Canadian Journal of Biochemistry and Cell Biology
6. Molecular Endocrinology
7. Journal of Biological Chemistry

STUDY SECTIONS, REVIEWER PANELS:
1974 - present NSF
1974 NICHD
1984 Special Study Section For Program Project Grants

COMMUNITY SERVICES AND ORGANIZATIONAL MEMBERSHIPS:
1980 Rubicon Lodge #237 F.& A.M.
1981 Scottish Rite Valley of Toledo
1981 York Rite
1981 Zenobia Shrine
1984 Downtown Kiwanis (Toledo)
1985 Area Council for Technology
1994 The Toledo Club
1999 Rockwell Springs Trout Club

SERVICE OF INSTITUTIONAL COMMITTEES:
1974 - 1975 Reproductive Biology Committee
1976 - 1977 Faculty Senate
1978 - 1979 Membership Committee of the College of Graduate Studies
1979 - 1980 Chairman, Membership Committee of the Graduate School
1979 - 1980 Phase III Curriculum Committee
1980 - 1984 Committee on Human Rights in Research
1983 - 1986 Subcommittee Promotion and Tenure Committee
1988 - 1991 Distinguished Lecturers Committee
1989 - 1991 Search Committee for Chairman of Ob/Gyn
1990 - 1992 Standing Committee for Research Space
1990 - present Representative of the College of Graduate Studies at various thesis defenses
1992 - present BioMedical Research Support Committee
1992 - 1994 Disaster Preparedness Committee
1994 - present Search Committee for Physiology Faculty
1994 - 1996 Core Curriculum Committee of the Graduate School
1995 - present Numerous Graduate Student Committees at MUO and the University of Toledo, (3 Masters and 3 Ph.D.)
1995 - present Chairman of the Ad Hoc Committee on Promotions of the Department of Physiology and Molecular Medicine
1996 LCME Self Study Committee on Library and Computers
1996 LCME Self Study Committee on Administration and Governance
1996 - 1997 Ad Hoc Committee to Review MUO Intellectual Property Policies
1996 - 1997 Steering Committee, Molecular and Cell Biology, Ph.D. Program
1996 - present Patent and Intellectual Property Committee
1996 - present Department of Physiology Graduate Education Committee
1996 - present Molecular and Cellular Biology Program Core Curriculum Committee
1997 - present Molecular and Cellular Biology Program Steering Committee

TEACHING RESPONSIBILITIES:

A. PRESENT (ACTIVE)
1. Methods in Molecular and Cellular Biology
2. Nursing 257, Neurophysiology and Endocrinology
3. Pathophysiology, Problem Base Learning
4. MCB-1 (Molecular Cell BIology)

B. PAST (INACTIVE)

1. Reproductive Endocrinology - Ob/Gyn Residency
2. Mechanisms of Steroid Action - 1st Year Medical Students
3. Continuing Medical Education - Breast Cancer - Department of Medicine
4. Reproductive Physiology - College of Graduate Studies, Also Nursing
5. Benign Prostatic Hypertrophy - Residency Program, Department of Surgery

MISC. ADMINISTRATIVE ACTIVITIES:
1974 Set Up the Endocrine Research Unit
1974 Acquired the Money and Set Up the Laboratories in Rooms 435-438 in The Health Science Building
1975 Set Up the Billstein Ligand Laboratory (Now Special Chemistry)
1979 Set Up the Pelvic Model Program, Department of Ob/Gyn, Medical University of Ohio
1990 Organized the First International Meeting on Oligomeric Steroid Hormone Receptors
1998 Chairman, Class of 1964 Network Committee, Duke University
1999 Chairman, Class of 1964 Reunion, Duke University

INVITED LECTURES, SEMINARS, SYMPOSIA, VISITING PROFESSORSHIPS:
1972, 1981 Department of Biology, University of Toledo; Toledo, OH
1972, 1974, 1976, 1983,1999 Reproductive Endocrinology Program, University of Michigan; Ann Arbor, MI
1973 Department of Chemistry, Bowling Green State University; Bowling Green, OH
1976 Imperial Cancer Research Fund; London, England
1977 Abteilung Anat.; Medizin.-Theoret. Inst., Aachen, Germany
1978 Department of Animal Science, University of Wisconsin; Madison, WI
1978 Department of Molecular Medicine, Mayo Clinic; Rochester, MN
1978 NICHD; Bethesda, MD
1979 Department of Obstetrics & Gynecology, Harvard Medical School; Boston, MA
1979 Institute of Experimental Endocrinology; Bratslava, Czechoslovakia
1980 Interdepartmental Seminar Program, Indiana University; Bloomington, IN
1980 Department of Biology, Oakland University; Rochester, MI
1981 Department of Biology, Texas Tech. University, Lubbock, TX
1983 Burroughs Wellcome Corporation, Research Triangle Park; Raleigh/Durham, NC
1988 I.N.S.E.R.M. - Unit 33; Paris, France
1988 I.N.S.E.R.M. - Unit 33; 2 month leave of absence
1990 Oligomeric Steroid Receptors; Toledo, OH
1992 Upjohn Corporation, Kalamazoo, MI
1992 Merck, Sharp and Dohme, Rahway, NJ
1993 Ortho Pharmaceuticals, Raritan, NJ
1997 University of Texas Medical Branch at Galveston, Galveston, TX
1998 Ohio Physiological Society, Dayton, OH
1999 Sabbatical — University of Michigan, Ann Arbor, MI

PRESENTATIONS AT NATIONAL AND INTERNATIONAL MEETINGS:

1. From 1972 until the present over 30 presentations by either myself or members of my group (See Abstract Section in the Bibliography).
2. Chaired a session on Receptors and Cancer as part of The University of Michigan Continuing Education Program in 1975.
3. In 1983 presented the research aspects of the Department of Ob/Gyn to the Toledo Area Health Coalition. 

CONSULTATIVE ACTIVITIES:

Beckman Instruments, Owens Illinois, Stressgen

MAJOR RESEARCH INTERESTS:
 Historically our research interest has involved the purification and characterization of the nontransformed mammalian progestin receptor system. These studies were initiated in 1971 and continue today. Over the course of these researches, we discovered p59, a ubiquitous receptor associated protein. This was made possible by the development of KN382/EC1, a hybridoma secreting an anti-p59 antibody. Our laboratory is the sole source of the antibody and as such we are shipping it to workers around the world. A list of recipients follows:

1. Unit 33, I.N.S.E.R.M. - Paris, France
2. Mayo Medical School - Rochester, Minnesota
3. University of Michigan - Ann Arbor, Michigan
4. Dartmouth Medical School - Hanover, New Hampshire
5. Oregon Regional Primate Center - Portland, Oregon
6. University of Toronto - Toronto, Canada
7. University of Heidelberg - Heidelberg, West Germany
8. Lady Davis Institute - Montreal, Canada
9. State University of New York - Stony Brook, New York
10. National Cancer Institute - Frederick, Maryland
11. Saint Louis University - St. Louis, Missouri
12. University of Manitoba - Winnipeg, Canada
13. Osaka Medical School - Osaka, Japan
14. University of Sherbrooke - Sherbrooke, Canada
15. University of Calgary - Calgary, Canada
16. Structural Biochemistry Laboratory - Lille, France
17. Medical College of Wisconsin - Milwaukee, Wisconsin
18. Purdue University - West Lafayette, Indiana
19. National Institute Diabetes and Diseases of the Kidney - Bethesda, Maryland
20. Oklahoma State University - Stillwater, Oklahoma
21. Baylor College of Medicine - Houston, Texas
22. University of Athens - Athens, Greece
23. Fels Research Institute - Philadelphia, Pennsylvania
24. University of California at San Francisco
25. European Molecular Biology Laboratory - Heidelberg, Germany
26. University of Ottawa - Ottawa, Canada
27. Erasmus University - Rotterdam, Netherlands
28. Aarhus University - Aarhus, Denmark
29. Genetics and Toxicology Institute - Karlesrule, Germany
30. University of Western Australia
31. New York University - New York, New York
32. National Cancer Institute - Bethesda, Maryland
33. Department of Pharmacology, Medical University of Ohio - Toledo, OH
34. Harvard University - Cambridge, Massachusetts
35. University of North Carolina - Chapel Hill, North Carolina
36. University of Kentucky, Lexington, Kentucky
37. Semmelweis University, Budapest, Hungary
38. Upjohn Corporation, Kalamazoo, Michigan
39. Merck, Sharp and Dohme, Rahway, New Jersey
40. Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts
41. Columbia University, New York, New York
42. Yale University, New Haven, Connecticut
43. Glaxo Inc., Research Triangle Park, North Carolina
44. Universidad Autonoma de Madrid, Madrid, Spain
45. Ludwig Institute for Cancer Research, London, England
46. Universita Degli Studi de Modena, Modena, Italy
47. University College London, London, England
48. University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey
49. University of Texas, Dallas, Texas
50. Iwate Medical University, Iwate, Japan
51. Albert-Ludwigs-University, Freiberg, Germany
52. Tel Aviv University, Tel Aviv, Israel
 
Our research currently involves the study of the interactions of p59 (FKBP59) and heat shock proteins with members of steroid/thyroid superfamily of regulatory proteins.
We are presently studying induction of proteins in S phase by estrogen in breast cancer cells. This is a novel approach coupling a new method cell cycle synchronization with flow cytometry and Ciphergen's SELDI ProteinChip technology. Basically this is bio-marker discovery.
We have recently developed a collaborative project with Drs. Jerry Menon and Roland Kwok at the University of Michigan. We are studying the role of CBP (CREB Binding Protein) in the induction of cell cycle regulatory proteins in granulosa cells.

PAST, CURRENT AND PENDING RESEARCH SUPPORT, TRAINING GRANTS:

A. External Sources
Progesterone Receptors (Principal Investigator)
Toledo Hospital 06/01/74 - 05/31/77 $ 152,000

Equipment (Principal Investigator)
Toledo Hospital 06/01/74 $ 150,000

The Study of Progesterone Binding Proteins as Tool for Detection of Progesterone Antagonists and Agonists #N01-HD-42851 (Principal Investigator)
NICHD 06/01/74 - 05/31/75 $ 92,059

Progesterone Receptors
HD-09367
(Principal Investigator)
NICHD 06/01/75 - 06/31/83 $ 341,248
$ 162,034*

Progesterone Receptors in Hyperplasia of the Prostate
(Principal Investigator)
Ohio Board of Regents 07/01/80 - 06/31/82 $ 9,600
Progesterone Receptors in the Aging Prostate AG-02776 (Principal Investigator)
NIA 03/01/82 $ 225,425, $ 107,077*
Progesterone Receptors HD-09367-07 (Principal Investigator)
NICHD 07/01/83 - 02/01/87 $ 263,082, $ 124,964*

L7-55 Ultracentrifuge
Beckman Instruments
04/16/86 $ 24,000

Travel Grant
Ligue Francaise Contre Le Cancer
01/31/88 - 04/01/88 ff 20,000

Characterization of p59 DK-41881 (Principal Investigator)
NIDDK 07/01/89 - 06/30/92 $ 247,070
$122,830*

Oligomeric Steroid Receptors
Syntex Research 04/06/90 $ 500

Oligomeric Steroid Receptors - 25th Annual Anniversary Committee
  04/06/90 $ 1,800

Growth Factors and Steroid Receptor Transformation HD-28034 (Principal Investigator)
NICHD 09/01/91 - 08/31/93 $ 100,000

Characterization of p59 A1-34774 (Principal Investigator)
NIAID 03/01/93 - 02/28/98 $ 660,636

Institutional Pre-Doctoral T32-CA79450-01 (Preceptor) (Ming You - Principal Investigator) NRSA" NIH/NCI 12/01/98 - 11/30/03 $ 144,804
    Total $ 2,928,229
*Indirect Cost

B. Pending Grants


Estrogen and Rapamycin NIH 07/01/00 - 06/30/02 $ 216,000

Dependent Markers  *Insight Awards to Stamp Out Breast Cancer

C. Internal Support

Progesterone Receptors BRS 1978 - 1979 $ 3,000
    1979 - 1980 $ 3,000
    1986 - 1987 $ 4,000
    1987 - 1988 $ 8,000

Research Challenge   1994 - 19 97 $ 60,000
     Total $ 78,000

POST-DOCTORAL FELLOWS:
* Ping K.-K. Tai, Ph.D.
* Kiyohide Nakao, M.D.
* Yoshiaki Maeda, M.D., Ph.D

Ph.D. STUDENT:
Haiyan Pang, Ph.D.

PATIENT/LICENSURES:
KN 82/EC1 Antibody to StressGen, 1995.

BIBLIOGRAPHY:

A. Completed Publications:
Someren, J.S., Faber, L.E., Klein, J.D., and Tumlin, J.A. Heat Shock Proteins 70 And 90 Increase Calcineurin Activity In Vitro Through Calmodulin-Dependent and Independent Mechanisms. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 260:619-625, 1999.

Tai, P.-K., K. Albers, M.W., McDonnel, D.P., Chang, H., Schreiber, S.L., and Faber, L.E., Potentiation of Progesterone Receptor-Mediated Transcription by the Immunosuppressant FK506. BIOCHEMISTRY 33:10666-10670, 1994.

Tai, P.-K.K., Chang, H., Albers, M.W., Schreiber, S.L., Toft, D.O., and Faber, L.E., P59 (FK506 Binding Protein 59) Interaction with Heat Shock Proteins is Highly Conserved and May Involve Proteins Other Than Steroid Receptors. BIOCHEMISTRY 32:8842-8847, 1993.

Tai, P.-K.K., Albers, M.W., Chang, H., Faber, L.E., and Schreiber, S.L., Association of a 59-kD Immunophilin with the Glucocorticoid Receptor Complex. SCIENCE (USA) 256:1315-1318, 1992.

Massol, N., Lebeau, M.-C., Renoir, J.M., Faber, L.E., and Baulieu, E.-E., Rabbit FKBP59-Heat Shock Protein Binding Immunophilin (HBI) is a Calmodulin Binding Protein. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 187:1330-1335, 1992.

Lebeau, M.-C., Massol, N., Herrick, J., Faber, L.E., Renoir, J.-M., Radanyi, C., and Baulieu, E.-E., P59, An hsp90-Binding Protein. JOURNAL OF BIOLOGICAL CHEMISTRY 267:4281-4284, 1992.

Wakim, N.G., Kim, K., Nordlund, D.J., Duhring, J.L., and Faber, L.E., Cytosolic and Nuclear Progesterone Receptors in Normal and Luteal Phase Defect Endometrial Cells. INTERNATIONAL JOURNAL OF FERTILITY 36(3):162-166, 1991.

Renoir, J.-M., Radanyi, C., Jung-Testas, I., Faber, L.E., and Baulieu, E.-E., The Non-Activated Progesterone Receptor is a Nuclear Heterooligomer. JOURNAL OF BIOLOGICAL CHEMISTRY 265:14402-14406, 1990.

Smith, D.F., Faber, L.E., and Toft, D.O., Purification of Unactivated Progesterone Receptor and Identification of Novel Receptor-Associated Proteins. JOURNAL OF BIOLOGICAL CHEMISTRY 265:3996-4003, 1990.

Sanchez, E.R., Faber, L.E., Henzel, W.J., and Pratt, W.B., The 56 kDa Protein in the Untransformed Human Glucocorticoid Receptor Complex is a Unique Protein That Exists in Cytosol in a Complex With Both the 70 kDa and 90 kDa Heat Shock Proteins. BIOCHEMISTRY 29:5145-5152, 1990.

Renoir, J.-M., Radanyi, C., Faber, L.E., and Baulieu, E.-E., A HSP 90-Bound 59 kDa Mr Protein (p59) is Involved in the Non-DNA Binding Heterooligomeric Form of Mammalian Steroid Hormone Receptors. JOURNAL OF BIOLOGICAL CHEMISTRY 265:10740-10745, 1990.

Gasc, J.-M., Renoir, J.-M., Faber, L.E., Delahaye, F., and Bauleiu, E.-E., Nuclear Localization of Two Steroid Receptor-Associated Proteins, Hsp 90 and p59. EXPERIMENTAL CELL RESEARCH 186:362-367, 1990.

Prokipcak, R.D., Faber, L.E., and Okey, A.B., Characterization of the Ah Receptor for 2,3,7,8-Tetrachlorodibenzo-p-Dioxin: Use of a Monoclonal Antibody Directed Against a 59 kD Protein Associated with Steroid Receptors. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS 247(2):648-658, 1989.

Belsham, D.D., Rosenmann, E., Pereira, F.A., Williams, S.G., Turney, M.K., Kovacs, W.J., Faber, L.E., and Wrogemann, K., The 56 kDa Protein of Human Genital Skin Fibroblasts Is Identical to that Radiolabelled b[3H]-Dihydrotestosterone 17b-Bromoacetate. JOURNAL OF STEROID BIOCHEMISTRY 33:389-394, 1989.

Faber, L.E., Wakim, N.G., and Duhring, J.L., Evolving Concepts in the Mechanism of Steroid Action. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY 156:1449-1458, 1987.

Tai, P.-K.K., Maeda, Y., Nakao, K., Wakim, N.G., Duhring, J.L., and Faber, L.E., A 59 kDa Protein Associated with Progestin, Estrogen, Androgen, and Glucocorticoid Receptors. BIOCHEMISTRY 25:5269-5275, 1986.

Tai, P.-K.K., and Faber, L.E., Isolation of Dissimilar Components of the 8.5S Nonactivated Rabbit Uterine Progestin Receptor. CANADIAN JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY 63:41-49, 1985.

Nakao, K., Myers, J.E., and Faber, L.E., Development of a Monoclonal Antibody to the Rabbit 8.5S Uterine Progestin Receptor. CANADIAN JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY 63:33-40, 1985.

Albert, J.D., Geller, J., Liu, J., and Faber, L.E., Tamoxifen Decreases Progesterone and Nuclear Androgen Receptors in the Human Prostate. JOURNAL OF STEROID BIOCHEMISTRY 21:659-666, 1984.

Liu, J., Albert, J.D., Geller, J., and Faber, L.E., Effect of Tamoxifen on Stromal Protein Synthesis in the Human Prostate. JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM 59:710-713, 1984.

Saffran, J., Loeser, B.K., and Faber, L.E., Effects of Progestins on the Progesterone Receptor in Guinea Pig Uterus. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 117:223-239, 1979.

Saffran, J., Loeser, B.K., Bohnett, S.A., Gray, M.A., and Faber, L.E., The Binding of 5-Pregnane-3, 20-dione by Cytosol and Nuclear Preparations of Guinea Pig Uterus. ENDOCRINOLOGY 102:1088-1098, 1978.

Faber, L.E., Sandmann, M.L., and Stavely, H.E., Effect of Buffers and Electrolytes on the Stability of Uterine Progesterone Receptors. BIOCHEMICAL MEDICINE 19:78-89, 1978.

Saffran, J., Loeser, B.K., Bohnett, S.A., and Faber, L.E., Binding of The Progesterone Receptor by Nuclear Preparations of Rabbit and Guinea Pig Uterus. JOURNAL OF BIOLOGICAL CHEMISTRY 251:5607-5613, 1976.

Faber, L.E., Saffran, J., Chen, T.J., and Leavitt, W.W., Mammalian Progesterone Receptors: Biosyntheses, Structure and Nuclear Binding. CURRENT TOPICS IN MOLECULAR ENDOCRINOLOGY 4:68-84, 1976.

Faber, L.E., Sandmann, M.L., and Stavely, H.E., Progesterone and Corticosterone Binding in Rabbit Uterine Cytosols. ENDOCRINOLOGY 93:74-80, 1973.

Faber, L.E., Sandmann, M.L., and Stavely, H.E., Progesterone Binding in Uterine Cytosols of the Guinea Pig. JOURNAL OF BIOLOGICAL CHEMISTRY 247:8000-8004, 1972.

Faber, L.E., Sandmann, M.L., and Stavely, H.E., Progesterone Binding Proteins of the Rat and Rabbit Uterus. JOURNAL OF BIOLOGICAL CHEMISTRY 247:5648-5649, 1972.

Faber, L.E., The Uptake and Distribution of 1,2-H3-Testosterone and 6,7-H3-Estradiol-A-B in the 20 Day Old Single Comb White Leghorn Cockerel and Capon, Indiana University Ph.D. Thesis, 1969.

 D. Chapters in Books:


Toft, D.U., and Faber, L.E., Mammalian FKBP12. IN: GUIDEBOOK TO MOLECULAR CHANGES AND PROTEIN-FOLDING CATALYSTS, Gething, M.J. ed., Oxford University Press, NY, p. 430-431, 1997.

Tai, P.-K.K. and Faber, L.E., Use of FK506 and its Analogues in Studying Progesterone Signaling. IN: SIGNALING IN ESTROGEN, PROGESTINS, AND THEIR ANTAGONIST, Pavlik, E., ed., Birkhaüser, Boston, Basel, Berlin, Vol. 2, p. 217-230, 1996.

Faber, L.E., Tai, P.-K.K., Maeda, T., Myers, J., and Nakao, K., Studies of the Subunit Composition of the 8.5S Rabbit Uterine Progestin Receptor, IN: MOLECULAR MECHANISM OF STEROID HORMONE ACTION, Moudgil, V.K. (Ed.), Walter DeGruyter & Co., Berlin, New York, NY, p.61-84, 1985.

Faber, L.E., The Mammalian Progestin Receptor: An Argument for the Biological Importance of the High Molecular Weight Forms, IN: STEROID INDUCED UTERINE PROTEINS, Beato, M. (Ed.), Elsevier/North Holland Press, Amsterdam, p.197-216, 1980.

Saffran, J., Loeser, B.K., and Faber, L.E., Effects of Progestins on The Progesterone Receptor in Guinea Pig Uterus, IN: STEROID HORMONE RECEPTOR SYSTEMS, Leavitt, W.W. and Clark, J. (Eds.), Advances in Experimental Medicine and Biology, Plenum Press, New York, NY, Vol. 117, p.223-239, 1979.

Faber, L.E., and Saffran, J., Studies on the Structure of Mammalian 7S Uterine Progesterone Receptor, IN: MULTIPLE MOLECULAR FORMS OF STEROID HORMONE RECEPTORS, Agarwal, M.K. (Ed.), Elsevier/North Holland Press, Amsterdam, p.149-161, 1977.

Faber, L.E., Saffran, J., Chen, T.J., and Leavitt, W.W., Mammalian Progesterone Receptors: Biosynthesis, Structure, and Nuclear Binding, IN: STEROID HORMONE ACTION AND CANCER, Menon, K.M.J. and Reel, J.R. (Eds.), Plenum Press, New York, NY, p.68-84, 1976.
 
E. Abstracts:


Pang, H., Faber, L.E., Use of Differential Display RT-PCR to Identify Genes Affected by R50020 and Epidermal Growth Factors in breast Cancer Cells. FASEB, Washington, D.C., LB 105, A23, 1998.

Tai, P.-K.K., Chang, H., Shemshedini, L. and Faber, L.E., Inhibition of [3H]-Thymidine Uptake in Breast Cancer Cells is Independent of the Activator Protein -1 (AP-1) Activity. The 77th Annual Meeting of THE ENDOCRINE SOCIETY, Washington, D.C., 1995.

Tai, P.-K.K., Chang, H., Albers, M.W., Schreiber, S.L., and Faber, L.E., FK506 Potentiates Progesterone Transactivation in FKBP12-Deficient Yeast Mutant. The 76th Annual Meeting of THE ENDOCRINE SOCIETY, Anaheim, CA, 1994.

Tai, P.-K.K., Chang, H., Jeng, R., Albers, M.W., Schreiber, S.L. and Faber, L.E., FK506 Potentiates Progesterone Transactivation. 75th Annual Meeting of THE ENDOCRINE SOCIETY, Las Vegas, NV, Abst. #13, 1993.

Faber, L.E., Tai, P.-K.K., Chang, H., Albers, M.W., and Schreiber, S.L., Immunophilin (P59, FKBP59) Heat Shock Protein Interaction is Highly Conserved. 75th Annual Meeting of THE ENDOCRINE SOCIETY, Las Vegas, NV, Abst. #25, 1993.

Tai, P.-K.K., Horrigan, T.J., Wakim, N.G., Renoir, M., and Faber, L.E., Dexamethasone and RU-486 Effects on Glucocorticoid Receptors in IM9 Lymphocytes. 73rd Annual Meeting of THE ENDOCRINE SOCIETY, Washington, D.C., Abst. #651, 1991.

Wakim, N.G., Faber, L.E., Tai, P.-K.K., Diebold, C.M., Identification of Spermatozoal Membrane Antigens In The Autoimmune Male Infertility Patient. 73rd Annual Meeting of THE ENDOCRINE SOCIETY, Washington, D.C., Abst. #1158, 1991.

Wakim, N.G., Faber, L.E., Hafer, M., Incidence of Interstitial Fallopian Tube Obstruction. Presented at the 19th Annual Meeting of the INTERNATIONAL CONGRESS OF GYNECOLOGIC ENDOSCOPY, Orlando, FL, November 14-18, 1990.

Wakim, N.G., Faber, L.E., and Hafer, M., Incidence of Interstitial Fallopian Tube Obstruction. Presented at the VII WORLD CONGRESS ON HUMAN REPRODUCTION, Helsinki, Finland, June 26-July 1, 1990.

Wakim, N.G., Deveny, T.C., Hermes, J., Faber, L.E., Schut, H., Hyperprolactinemia in Infertile Patients with Normal Luteal Phase and No Galactorrhea. Presented at the 45th Annual Meeting of THE AMERICAN FERTILITY SOCIETY, San Francisco, CA, November 11-17, 1989.

Wakim, N.G., Deveny, T.C., Hermes, J., Faber, L.E., and Schut, H., Hyperprolactinemia in Infertile Patients with Normal Luteal Phase and No Galactorrhea. Accepted by EUROPEAN SOCIETY OF HUMAN REPRODUCTION AND EMBRYOLOGY, Copenhagen, Denmark, 1989.

Faber, L.E., Renoir, J.M., and Baulieu, E.-E., Association of Both a MW 59,000 Nuclear Protein and a Heat Shock Protein (HSP90) With the Calf Uterine Nontransformed Estradiol Receptor. 71st Annual Meeting of THE ENDOCRINE SOCIETY, Seattle, WA, Abst. #933, 1989.

Renoir, J.M., Jung-Testas, I., Radanyi, C., Soltani, M., Akwa, Y., Faber, L.E., and Baulieu, E.-E., Isolation of Nuclear Nontransformer Progesterone-RU486 Complexes, Including HSP90 and P59. 71st Annual Meeting of THE ENDOCRINE SOCIETY, Seattle, WA, Abst. #992, 1989.

Prokipcak, R.D., Faber, L.E., and Okey, A.B., Characterization of the Ah Receptor for 2,3,7,8,-Tetrachlorodibenzo-p-Dioxin (TCDD): Use of a Monoclonal Antibody Directed Against the 59-kilodalton (59 kD) Protein Associated with Steroid Receptors. CANADIAN FEDERATION OF BIOLOGICAL SCIENCES, 1988.

Wakim, N.G., Maeda, Y., Nakao, K., Duhring, J.L., and Faber, L.E., Studies of the Structure of the Nontransformed Progestin Receptor. 1st Congress of the INTERNATIONAL SOCIETY OF GYNECOLOGICAL ENDOCRINOLOGY. Crans Montana, Switzerland, 1988.

Maeda, Y., Nakao, K., Wakim, N.G., Duhring, J.L., and Faber, L.E., Protein Components of Nontransformed Uterine Progestin Receptors. The Third INTERNATIONAL CONGRESS ON HORMONES AND CANCER, Hamburg, Germany, 1987.

Faber, L.E., Wakim, N.G., and Duhring, J.L., Evolving Concepts in The Mechanism of Steroid Action. 54th Annual Meeting of the CENTRAL ASSOCIATION OF OBSTETRICIANS AND GYNECOLOGISTS, Milwaukee, WI, 1986.

Wakim, N.G., Gregory, L., Kim, K., Duhring, J.L., and Faber, L.E., A Quantitative and Qualitative Study of Progesterone Receptors in Women with Luteal Phase Defect. 42nd Annual Meeting of

Maeda, Y., Nakao, K., Duhring, J.L., Wakim, N.G., and Faber, L.E., Immunological Studies of the Nontransformed Rabbit Uterine Progestin Receptor System. 68th Annual Meeting of THE ENDOCRINE SOCIETY, Anaheim, CA, Abst. #1001, 1986.

Tai, P.-K.K., Maeda, Y., and Faber, L.E., Immunological Studies of the Mr=59,000 Component of the Rabbit Uterine Progestin Receptor System. 67th Annual Meeting of THE ENDOCRINE SOCIETY, Baltimore, MD, p.86, Abst. #342, 1985.

Tai, P.-K.K., and Faber, L.E., Immunological Studies of the Subunit Structure of the 8.5S Rabbit Uterine Progestin Receptor. 7th INTERNATIONAL CONGRESS OF ENDOCRINOLOGY, Quebec City, Canada, Abst. #2705, 1984.

Albert, J., Geller, J., Liu, J., Tai, P.-K.K., and Faber, L.E., The Effects of Tamoxifen on Steroid Receptors in Human Prostate. 7th INTERNATIONAL CONGRESS OF ENDOCRINOLOGY, Quebec City, Canada, Abst. #223, 1984.

Faber, L.E., Nakao, K., and Myers, J.E., The Mammalian Progestin Receptor: Development of Cell Line KN382/EC1, a Mouse Hybridoma Producing an IgG1 Directed Against the 8.5S Rabbit Uterine Progestin Receptor. AMERICAN SOCIETY OF BIOLOGICAL CHEMISTRY Meeting, San Francisco, CA, Abst. #705, 1983.

Nakao, K., Myers, J.E., and Faber, L.E., The Mammalian Progestin Receptor: Development of Cell Line KN382/EC1, A Mouse Hybridoma Producing an IgG1 Directed Against the 8.5S Rabbit Uterine Progestin Receptor. 65th Annual Meeting of THE ENDOCRINE SOCIETY, San Antonio, TX, Abst. #775, 1983.

Nakao, K., Myers, J.E., and Faber, L.E., Purification of the 8.5S Guinea Pig Uterine Progestin Receptor: Detection of a 3S Form. 64th Annual Meeting of THE ENDOCRINE SOCIETY, San Francisco, CA, Abst. #1103, 1982.

Nakao, K., and Faber, L.E., The Rabbit Uterine Progestin Receptor: Detection of the 8.5S Complex. 63rd Annual Meeting of THE ENDOCRINE SOCIETY, Cincinnati, OH, Abst. #861, 1981.

Dyer, R.D., Myers, J.E., Nakao, K., and Faber, L.E., Purification of the 8.5S Form of the Guinea Pig and Rabbit Uterine Progestin Receptor. 63rd Annual Meeting of THE ENDOCRINE SOCIETY, Cincinnati, OH, Abst. #860, 1981.

Dyer, R.D., and Faber, L.E., Use of Spheroidal Hydroxylapatite Chromatography for Purification of the 7S Guinea Pig Uterine Progestin Receptor System. 62nd Annual Meeting of THE ENDOCRINE SOCIETY, Washington, D.C., Abst. #223, 1980.

Faber, L.E., The Mammalian Uterine Progesterone Receptor: An Argument for Biological Importance of the Larger Forms. 1st INTERNATIONAL CONGRESS ON HORMONES AND CANCER, Rome, Italy, 1979.

Faber, L.E., The Mammalian Uterine Progestin Receptor: An Argument for the Biological Importance of the Larger Forms, in the SYMPOSIUM ON PERSPECTIVES IN STEROID RECEPTOR RESEARCH, Sorrento, Italy, 1979.

Faber, L.E., The Mammalian Progestin Receptor: An Argument for the Biological Importance of the Larger Forms, in the SYMPOSIUM ON STEROID INDUCED UTERINE PROTEINS, Marburg/Lahn, Federal Republic of Germany, 1979.

Faber, L.E., The Progesterone Receptor, an Equilibrium Model, in the SYMPOSIUM ON STEROID RECEPTOR SYSTEM, Worcester Foundation for Experimental Biology, Shewsbury, MA, 1978.

Faber, L.E., Studies on the Structure of the Mammalian 7S Uterine Progesterone Receptor, ACTA ENDOCRINOLOGICA CONGRESS, Lausanne, Switzerland, 1977.

Faber, L.E., Molecular Forms of the Guinea Pig Uterine Progesterone Receptor, 5th INTERNATIONAL CONGRESS OF ENDOCRINOLOGY, Hamburg, Germany, 1976.

Faber, L.E., Sandmann, M.L., and Stavely, H.E., Effect on Buffers and Electrolytes on the Stability of Uterine Progesterone Receptors, FEDERATION PROCEEDINGS, 32(3):299, 1973.

Martin, E.W., and Faber, L.E., The Effects of Ultrasonic Sound on Auditory Pathway Potentials in the Laboratory Rat. AMERICAN ZOOLOGY, 7(2):189,1967.

 F. Manuscripts Submitted or in Preparation:

Pang, H., Tai, P.-K.K., and Faber, L.E., Use of Differential Display RT-PCR to Identify Differentially Expressed Gene Affected by Progestin and Epidermal Growth Factor in Breast Cancer Cells, (2000).

Pang, H., and Faber, L.E., Estrogen, Progestin, and Rapamycin Effects on Cell Cycle Division of T47D Breast Cancer Cells, (2000).

Pang, H., and Faber, L.E., Use of SELDI to Identify Estrogen Responsive Proteins, (2000).
Last Updated: 3/22/15